Calgary-based Resverlogix announced the addition  of Professor H. Bryan Brewer to Resverlogix's Clinical Steering Committee. 

Brewer, a cardiologist, is currently Director  of Lipoprotein and Atherosclerosis Research, Cardiovascular Research  Institute, Washington Hospital Center, Washington, D.C. He was the former chief of the Molecular Disease Branch  at the National Institute of Health, Bethesda, Md., and is a leader  and pioneer in the field of high density lipoprotein (HDL) research.  His seminal observations led to the cloning of the Apolipoprotein A-I (ApoA-I) mRNA and the gene. 

The availability of the ApoA-I mRNA and the gene enabled clinicians and scientists to understand the role of ApoA-I  protein in reverse cholesterol transport (RCT) and atherosclerosis  protection. 

"Professor Brewer is one of the most well-respected pioneers in the  field of HDL biology.  He has extensive industry expertise having  served as a consultant to major pharmaceutical companies including  Abbott, Lilly, Merck, Pfizer, Roche, Sanofi and  Schering-Plough.  These skills will enhance the activities of our clinical steering committee, which is instrumental in the design and conduct of Resverlogix's human clinical trials relating to its lead compound RVX-208," said Don McCaffrey, president and CEO. 

Dr. Jan Johansson, senior vice president of medical affairs of Resverlogix, said, "Dr. Brewer's joining our Clinical Steering  Committee further validates RVX-208's unique position in the critically  important atherosclerosis market. Our highly differentiated mechanism  in HDL biology, the raising of ApoA-I production and enhancement of RCT  biomarkers, is seen by many as the most logical approach to harness the  benefits of RCT and provide efficient reduction of atherosclerosis  burden from coronary arteries. If our lead drug RVX-208 can facilitate this type of effect in high risk CVD patients in only 26 weeks it will be positioned as a new breakthrough treatment for millions of patients  around the world."